JP2011520815A - 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 - Google Patents

精神神経障害治療のためのｎｍｄａ受容体拮抗薬 Download PDF

Info

Publication number
JP2011520815A
JP2011520815A JP2011508724A JP2011508724A JP2011520815A JP 2011520815 A JP2011520815 A JP 2011520815A JP 2011508724 A JP2011508724 A JP 2011508724A JP 2011508724 A JP2011508724 A JP 2011508724A JP 2011520815 A JP2011520815 A JP 2011520815A
Authority
JP
Japan
Prior art keywords
alkyl
carbon atoms
carbons
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520815A5 (https=
Inventor
デイングルデイーン，レイモンド・ジエイ
トレイネリス，ステイーブン・エフ
Original Assignee
エモリー・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー・ユニバーシテイ filed Critical エモリー・ユニバーシテイ
Publication of JP2011520815A publication Critical patent/JP2011520815A/ja
Publication of JP2011520815A5 publication Critical patent/JP2011520815A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011508724A 2008-05-09 2009-05-11 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 Pending JP2011520815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09
US61/127,098 2008-05-09
PCT/US2009/043502 WO2009137843A2 (en) 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
JP2011520815A true JP2011520815A (ja) 2011-07-21
JP2011520815A5 JP2011520815A5 (https=) 2012-06-21

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508724A Pending JP2011520815A (ja) 2008-05-09 2009-05-11 精神神経障害治療のためのｎｍｄａ受容体拮抗薬

Country Status (16)

Country Link
US (1) US20110160223A1 (https=)
EP (1) EP2296658A4 (https=)
JP (1) JP2011520815A (https=)
KR (1) KR20110016891A (https=)
CN (1) CN102762207A (https=)
AU (1) AU2009244082A1 (https=)
BR (1) BRPI0912362A2 (https=)
CA (1) CA2722776A1 (https=)
CO (1) CO6341558A2 (https=)
EA (1) EA020339B1 (https=)
IL (1) IL208895A0 (https=)
MX (1) MX2010012186A (https=)
NZ (1) NZ589764A (https=)
SG (1) SG195568A1 (https=)
WO (1) WO2009137843A2 (https=)
ZA (1) ZA201007958B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130668A (ja) * 2015-07-06 2022-09-06 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SG11201702799UA (en) * 2014-10-07 2017-05-30 Sage Therapeutics Inc Neuroactive compounds and methods of use thereof
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CN109803656B (zh) * 2017-10-09 2021-08-31 华南农业大学 一种抗白色念珠菌的化合物及其制备方法和应用
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
JP2021529732A (ja) 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
CN118019541A (zh) * 2021-09-02 2024-05-10 埃默里大学 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS54160389A (en) * 1978-06-06 1979-12-19 Hoechst Ag Novel substituted phenylpiperazine derivative and its manufacture
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
JPS61129167A (ja) * 1984-11-22 1986-06-17 ヘキスト・アクチエンゲゼルシヤフト 新規な置換されたフエニルピペラジン誘導体、それらの製造法およびそれらの用途
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
JP2001507721A (ja) * 1997-10-31 2001-06-12 サントリー株式会社 アリールピペリジノプロパノール及びアリールピペラジノプロパノール誘導体並びにそれらを含む医薬
WO2004035534A2 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue verbindungen mit dopaminerger und/oder serotoninerger aktivität
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2006010968A1 (en) * 2004-07-29 2006-02-02 Richter Gedeon Vegyészeti Gyár Rt. New aryloxy acetic acid amide derivatives
JP2006528236A (ja) * 2003-05-16 2006-12-14 ファイザー・プロダクツ・インク ジプラシドンを用いて認知を増強する方法
WO2007006738A2 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire
JP2007091733A (ja) * 2005-08-31 2007-04-12 Otsuka Pharmaceut Co Ltd 複素環化合物
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
AU2001296994A1 (en) * 2000-10-06 2002-04-15 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
EP1791569A4 (en) * 2004-08-23 2009-12-16 Univ Emory Improved selection of-ph dependent compounds for in vivo therapy
KR20100045983A (ko) * 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS54160389A (en) * 1978-06-06 1979-12-19 Hoechst Ag Novel substituted phenylpiperazine derivative and its manufacture
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
JPS61129167A (ja) * 1984-11-22 1986-06-17 ヘキスト・アクチエンゲゼルシヤフト 新規な置換されたフエニルピペラジン誘導体、それらの製造法およびそれらの用途
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
JP2001507721A (ja) * 1997-10-31 2001-06-12 サントリー株式会社 アリールピペリジノプロパノール及びアリールピペラジノプロパノール誘導体並びにそれらを含む医薬
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2004035534A2 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue verbindungen mit dopaminerger und/oder serotoninerger aktivität
JP2006528236A (ja) * 2003-05-16 2006-12-14 ファイザー・プロダクツ・インク ジプラシドンを用いて認知を増強する方法
WO2006010968A1 (en) * 2004-07-29 2006-02-02 Richter Gedeon Vegyészeti Gyár Rt. New aryloxy acetic acid amide derivatives
WO2007006738A2 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire
JP2007091733A (ja) * 2005-08-31 2007-04-12 Otsuka Pharmaceut Co Ltd 複素環化合物
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEM PHARM BULL, vol. 36, no. 11, JPN6013055772, 1988, pages 4377 - 4388, ISSN: 0002678087 *
INDIAN JOURNAL OF CHEMISTRY, vol. 15, JPN7013002063, 1977, pages 466 - 472, ISSN: 0002678085 *
INDIAN JOURNAL OF CHEMISTRY, vol. 21, JPN7013002060, 1982, pages 914 - 918, ISSN: 0002678084 *
J MED CHEM, vol. 41, JPN6013055775, 1998, pages 658 - 667, ISSN: 0002678088 *
LIFE SCIENCES, vol. 43, JPN6013055770, 1988, pages 263 - 269, ISSN: 0002678086 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130668A (ja) * 2015-07-06 2022-09-06 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
JP7478190B2 (ja) 2015-07-06 2024-05-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法

Also Published As

Publication number Publication date
BRPI0912362A2 (pt) 2015-10-06
CN102762207A (zh) 2012-10-31
US20110160223A1 (en) 2011-06-30
CA2722776A1 (en) 2009-11-12
EA020339B1 (ru) 2014-10-30
ZA201007958B (en) 2011-07-27
KR20110016891A (ko) 2011-02-18
EP2296658A4 (en) 2014-01-15
MX2010012186A (es) 2011-02-22
EP2296658A2 (en) 2011-03-23
NZ589764A (en) 2012-10-26
WO2009137843A2 (en) 2009-11-12
EA201071291A3 (ru) 2014-02-28
IL208895A0 (en) 2011-01-31
CO6341558A2 (es) 2011-11-21
SG195568A1 (en) 2013-12-30
AU2009244082A1 (en) 2009-11-12
WO2009137843A9 (en) 2010-03-11
EA201071291A2 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
JP2011520815A (ja) 精神神経障害治療のためのｎｍｄａ受容体拮抗薬
EP2170334B1 (en) Nmda receptor antagonists for neuroprotection
US9278943B2 (en) Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
CN107840845B (zh) 胺类化合物的新用途
CN105130957A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
US20150183741A1 (en) Compounds that are s1p modulating agents and/or atx modulating agents
US20140148432A1 (en) Compounds for the Treatment of Neurological Disorders
JP2018527354A (ja) ６員アザヘテロ環を含有するデルタ−オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
RS55916B1 (sr) Derivati aminociklobutana, metod za dobijanje istih i njihova upotreba kao lekova
US20250129064A1 (en) Prodrugs of 2-bromo-lsd (2-bromolysergic acid diethylamide)
CN110770209B (zh) 用作p2x1及p2x3受体拮抗剂的新型5-羟基吡啶类化合物及包含其的药物组合物
US20120088800A1 (en) 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS
AU2013203941A1 (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
EP2229361A1 (en) Tetrahydroindoles having sphingosine-1-phosphate receptor activity
AU2013203908A1 (en) Compounds for the treatment of neurologic disorders
NZ623571A (en) Dosage regimen for an s1p receptor modulator or agonist
HK1240927B (zh) 氨基环丁烷衍生物、其制备方法及其用作药物的用途
HK1211236B (en) 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (s1p) receptor and/or autotaxin (atx) modulators for treating inflammatory and autoimmune disorders
NZ623571B2 (en) Dosage regimen for an s1p receptor modulator or agonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140715